Cynosure Beats Up on Analysts Yet Again
Cynosure (NAS: CYNO) reported earnings on Feb. 14. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Cynosure beat expectations on revenue and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly, and GAAP earnings per share expanded.
Margins increased across the board.
Cynosure recorded revenue of $34.1 million. The four analysts polled by S&P Capital IQ hoped for sales of $33.3 million on the same basis. GAAP reported sales were 53% higher than the prior-year quarter's $22.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.08. The four earnings estimates compiled by S&P Capital IQ predicted $0.05 per share. GAAP EPS were $0.08 for Q4 versus -$0.07 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 56.3%, 40 basis points better than the prior-year quarter. Operating margin was 4.2%, 700 basis points better than the prior-year quarter. Net margin was 3.2%, 680 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $30.5 million. On the bottom line, the average EPS estimate is -$0.04.
Next year's average estimate for revenue is $135.5 million. The average EPS estimate is $0.17.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 369 members rating the stock outperform and 10 members rating it underperform. Among 107 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 105 give Cynosure a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cynosure is outperform, with an average price target of $17.50.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Cynosure performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add Cynosure to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.